Clinical outcome assessment trends in neuro-oncology trials
Our computational assessment highlights low but increasing COA adoption in neuro-oncology trials, mirroring broader oncology trends and reflecting a cumulative impact of regulatory and advocacy efforts. Priority areas for improvement include early-phase trials, FDA-approved interventions, and treatment-focused studies. Our findings emphasize the need for COA-specific reporting improvements and greater standardization in neuro-oncology research.
Authors
- Terri S. Armstrong (ORCID: https://orcid.org/0000-0002-2414-0492)
- Mark R. Gilbert (ORCID: https://orcid.org/0000-0001-8935-1744)
- Orieta Celiku (ORCID: https://orcid.org/0000-0002-0500-1032)
- Yeonju Kim (ORCID: https://orcid.org/0000-0001-9220-4315)
Institutions
- National Institutes of Health (US)
- Wayne State University (US)
- Center for Information Technology (US)
- National Cancer Institute (US)
- Department of Health and Human Services (US)
Publication Details
- Journal
- Neuro-Oncology Practice
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/nop/npaf065
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63